Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

NCT06670222 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Low-risk Myelodysplastic Syndromes

Interventions

DRUG: Arsenic Trioxide (ATO)

Sponsor

Groupe Francophone des Myelodysplasies